CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-26 | Hohl Benjamin Chief Financial Officer | Option exercise 10b5-1 | +100 | $2.48 | $248 | 100 |
| 2023-12-26 | Hohl Benjamin Chief Financial Officer | Sale 10b5-1 | −100 | $15.00 | $2K | 0 |
| 2023-12-26 | Hohl Benjamin Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −100 | 260,990 | ||
| 2023-12-22 | Patel Anish Chief Operating Officer | Sale 10b5-1 | −983 | $15.03 | $15K | 35,739 |
| 2023-12-22 | Hohl Benjamin Chief Financial Officer | Option exercise 10b5-1 | +1,030 | $2.48 | $3K | 1,030 |
| 2023-12-22 | Hohl Benjamin Chief Financial Officer | Sale 10b5-1 | −1,030 | $15.07 | $16K | 0 |
| 2023-12-22 | Hohl Benjamin Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,030 | 261,090 | ||
| 2023-12-22 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +6,546 | $1.12 | $7K | 6,546 |
| 2023-12-22 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −6,546 | $13.07 | $86K | 0 |
| 2023-12-22 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −6,546 | 308,550 | ||
| 2023-12-22 | Kintz Samuel President and CEO | Option exercise | +8,175 | $1.12 | $9K | 8,175 |
| 2023-12-22 | Kintz Samuel President and CEO | Sale | −8,175 | $13.05 | $107K | 0 |
| 2023-12-22 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) | −8,175 | 308,550 | ||
| 2023-12-22 | Heyman Richard A. Director | Sale 10b5-1 | −168 | $13.00 | $2K | 147,280 |
| 2023-12-22 | Heyman Richard A. Director | Sale 10b5-1 | −35 | $13.00 | $455 | 29,216 |
| 2023-12-21 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +20 | $1.12 | $22 | 20 |
| 2023-12-21 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −20 | $13.00 | $260 | 0 |
| 2023-12-21 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20 | 315,096 | ||
| 2023-12-21 | Kintz Samuel President and CEO | Option exercise | +20 | $1.12 | $22 | 20 |
| 2023-12-21 | Kintz Samuel President and CEO | Sale | −20 | $13.00 | $260 | 0 |
Page 28 of 37 · 724 trades